Home > Clinical Trials
Check All Search

Saved trials

COMPLETED
NCT00221754
Pravastatin and Protease Inhibitors in HIV-infected Patients
21 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
HIV Infection


Hypercholesterolemia
NOT_YET_RECRUITING
NCT07578116
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis
562 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE3)
Anatomic Stage IV Breast Cancer AJCC v8


Metastatic HER2-Positive Breast Carcinoma


Oligometastatic Breast Carcinoma
ACTIVE_NOT_RECRUITING
NCT04704934
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
490 Enrollment(s)
156 Study location(s)
INTERVENTIONAL (PHASE3)
Gastric Cancer, Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
ACTIVE_NOT_RECRUITING
NCT04618913
Anticoagulation in Patients With Venous Thromboembolism and Cancer
1 Enrollment(s)
1 Study location(s)
OBSERVATIONAL (None)
Neoplasms


Embolism
RECRUITING
NCT06551220
Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
800 Enrollment(s)
26 Study location(s)
OBSERVATIONAL (None)
Metastatic Breast Cancer
ACTIVE_NOT_RECRUITING
NCT04622319
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
1,600 Enrollment(s)
482 Study location(s)
INTERVENTIONAL (PHASE3)
HER2-Positive Primary Breast Cancer


Residual Invasive Breast Cancer
RECRUITING
NCT07582887
Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response
70 Enrollment(s)
1 Study location(s)
OBSERVATIONAL (None)
Breast Cancer


Metastatic Breast Cancer


Drug-Related Side Effects and Adverse Reactions


Pharmacogenetic Variant
RECRUITING
NCT07582835
Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.
355 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE3)
Coronary Artery Disease


Percutaneous Coronary Intervention


Acute Coronary Syndromes


Antiplatelet Therapy


Single Antiplatelet Therapy


Coagulation Factors